Multipurpose Prevention Technologies (MPTs) are an innovative class of products that deliver varied combinations of HIV prevention, other STI prevention, and contraception and will improve the lives of women and families worldwide.
This database includes MPT products candidates that are currently funded and in active development as of August 2026. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding.
Search MPT Product Development Database
Click on the product name for more details.
- Etonogestrel
- Ethinyl Estradiol
- QGRFT
- Oak Crest Institute of Science
- Population Council
- Pre1
- HIV
- Unintended Pregnancy
- Nonoxinol
- National Research Institute for Family Planning, China
- C2
- Bacterial STI's
- Unintended Pregnancy
- Levonorgestrel
- ARV (unspecified)
- CONRAD
- Pre1
- HIV
- Unintended Pregnancy
- Cabotegravir
- Levonorgestrel
- CONRAD
- Pre1
- HIV
- Unintended Pregnancy
- Copper
- Lactide
- Population Council
- Queen's University Belfast
- Weill Cornell Medical College
- Pre1
- Bacterial Vaginosis (BV)
- Chlamydia
- Gonorrhea
- HIV
- HSV-2
- Unintended Pregnancy
- Dapivirine
- Levonorgestrel
- Population Council
- C1
- HIV
- Unintended Pregnancy
- Dapivirine
- Levonorgestrel
- Pritelivir
- University of North Carolina, Chapel Hill
- Pre1
- HIV
- HSV-2
- Unintended Pregnancy
- Dapivirine
- Levonorgestrel
- Magee-Women's Research Inst. & Foundation
- University of Pittsburgh
- Pre1
- HIV
- Unintended Pregnancy
- Emtricitabine (FTC)
- Ethinyl Estradiol (EE)
- Levonorgestrel
- Tenofovir Disoproxil Fumarate (TDF)
- Viatris
- Submitted for WHO PQ approval
- HIV
- Unintended Pregnancy
- Griffithsin (GRFT)
- Unspecified
- SwiftPharma
- Pre-formulation
- HIV
- HPV
- HSV-1
- HSV-2
- Etonogestrel
- Ethinyl Estradiol
- Islatravir (EFdA)
- University of North Carolina, Chapel Hill
- Pre1
- HIV
- Unintended Pregnancy
- Etonogestrel
- Islatravir (EFdA)
- Lenacapavir
- University of Washington
- Methodist Hospital Research Institute (HMRI)
- Pre1
- HIV
- Unintended Pregnancy
- Copper
- ARV (unspecified)
- University of Washington
- Pre1
- HIV
- Unintended Pregnancy
- Monoclonal Antibodies
- Magee-Women's Research Inst. & Foundation
- University of Pittsburgh
- Pre1
- HIV
- HSV-2
- Unintended Pregnancy
- Norelgestromin
- ARV candidates under review
- PATH
- Queen's University Belfast
- Pre1
- HIV
- Unintended Pregnancy
- Soluble adenylyl cyclase (sAC)
- Antiviral peptide lead candidate
- Oak Crest Institute of Science
- Pre2
- HSV-1
- HSV-2
- Unintended Pregnancy
- QGRFT
- Organic acids
- Population Council
- Pre1
- Bacterial Vaginosis (BV)
- Chlamydia
- Gonorrhea
- HIV
- HSV-2
- Unintended Pregnancy
- Tenofovir (TFV)
- Nifedipine (NFP)
- University of Lagos
- Pre1
- HIV
- Unintended Pregnancy
- Monoclonal Antibodies
- Tenofovir Disoproxil Fumarate (TDF)
- Oak Crest Institute of Science
- University of North Carolina, Chapel Hill
- Pre1
- HIV
- Unintended Pregnancy
- Polyphenylene Carboxymethylene (PPCM)
- Yaso Therapeutics
- C1
- Gonorrhea
- HSV-2
- Unintended Pregnancy
- Progestin
- ARV (unspecified)
- Magee-Women's Research Inst. & Foundation
- University of Pittsburgh
- Pre1
- HIV
- Unintended Pregnancy
- Elvitegravir
- Tenofovir Alafenamide (TAF)
- CONRAD
- C2
- HIV
- HSV-2
- Elvitegravir
- Tenofovir Alafenamide (TAF)
- Doxycycline
- CONRAD
- C1
- IND-Enabling
- Chlamydia
- HIV
- HSV-2
- Bacterial STI's
- Levonorgestrel
- Tenofovir (TFV)
- University of Lagos
- Pre1
- HIV
- Other Sexually Transmitted Infections (STI)
- Unintended Pregnancy
- Tenofovir (TFV)
- Gossypol acetate
- Nitroglycerin (TGN)
- Beijing Institute of Geriatrics, North Carolina State University
- Pre1
- Bacterial STI's
- Unintended Pregnancy
- Cabotegravir
- Medroxyprogesterone Acetate (MPA)
- University of North Carolina, Chapel Hill
- Pre1
- HIV
- Unintended Pregnancy
Download graphics of MPT products in the development pipeline as of August 2026:
If you refer to this database, please use the following suggested citation: The IMPT. (2026). MPT Product Development Database. MPTs101.org.
Click below for MPT products in the development pipeline, listed by:
On behalf of the IMPT, we extend our sincere appreciation to the following colleagues for their expert review of the MPT Pipeline Database:
Leigh Allen (NIH/NICHD), James Cummins (NIH/NIAID), Alison Footman (AVAC), Audrey Fratus (CTI Exchange), Jonathon Glock (NIH/NIAID), Emily Hoppes (CTI Exchange), and Logan Nickels (MCI).
Their time, insight, and commitment to strengthening the MPT field are deeply valued.
Resources on single indication products
- Calliope, the Contraceptive Pipeline Database, includes information about more than 170 contraceptive leads and products, including male and female targets and hormonal and non-hormonal methods. Visit the Calliope database at pipeline.ctiexchange.org.
- The Contraceptive Technology Innovation (CTI) Exchange is a platform for increasing global access to resources on contraceptive research, development, registration, and introduction through collaboration and knowledge sharing. Visit the CTI Exchange at www.ctiexchange.org.
- The HIV Prevention Research & Development Database (PxRD) is a comprehensive resource on biomedical HIV prevention clinical trials that are planned, ongoing or completed. Visit the PxRD database at www.avac.org/pxrd.
Feedback
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!